HomeAI · summaries
Storia in 3 fonti
AbbVie clinches FDA approval for ultra-rare blood cancer ADC from ImmunoGen purchase
AbbVie said the FDA has approved an antibody-drug conjugate it obtained as a part of its $10.1 billion buyout of ImmunoGen for an ultra-rare but aggressive form of blood cancer.
Confronto fonti
3 prospettive sulla stessa storiaTimeline cronologica
- ·
endpoints.news
AbbVie clinches FDA approval for ultra-rare blood cancer ADC from ImmunoGen purchase
AbbVie said the FDA has approved an antibody-drug conjugate it obtained as a part of its $10.1 billion buyout of ImmunoGen for an ultra-rare but aggressive form of blood cancer.
- ·
fiercepharma.com
With Elahere building steam, AbbVie nets FDA nod for another ImmunoGen cancer asset
As AbbVie continues to capitalize on its deal for ImmunoGen with the growth of commercial antibody-drug conjugate (ADC) Elahere, another of the acquired company’s clinical assets…
- ·
pharmaceutical-technology.com
FDA oncology roundup: AbbVie’s rare cancer approval, AstraZeneca in breast cancer limbo - Pharmaceutical Technology
AbbVie’s ultra-rare blood cancer ADC secured FDA clearance while AstraZeneca’s oral SERD for breast cancer remains in regulatory limbo.